- Home
- KLG vs MNKD Comparison
KLG vs MNKD Comparison
Compare KLG & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLG
- MNKD
- Stock Information
- Founded
- KLG 2022
- MNKD 1991
- Country
- KLG United States
- MNKD United States
- Employees
- KLG N/A
- MNKD N/A
- Industry
- KLG Packaged Foods
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- KLG Consumer Staples
- MNKD Health Care
- Exchange
- KLG Nasdaq
- MNKD Nasdaq
- Market Cap
- KLG 1.5B
- MNKD 1.4B
- IPO Year
- KLG N/A
- MNKD 2004
- Fundamental
- Price
- KLG $17.52
- MNKD $3.60
- Analyst Decision
- KLG Sell
- MNKD Buy
- Analyst Count
- KLG 7
- MNKD 4
- Target Price
- KLG $16.86
- MNKD $9.75
- AVG Volume (30 Days)
- KLG 959.1K
- MNKD 3.5M
- Earning Date
- KLG 08-05-2025
- MNKD 08-06-2025
- Dividend Yield
- KLG 3.77%
- MNKD N/A
- EPS Growth
- KLG N/A
- MNKD 228.27
- EPS
- KLG 0.65
- MNKD 0.10
- Revenue
- KLG $2,664,000,000.00
- MNKD $297,595,000.00
- Revenue This Year
- KLG N/A
- MNKD $13.72
- Revenue Next Year
- KLG N/A
- MNKD $15.21
- P/E Ratio
- KLG $26.87
- MNKD $34.71
- Revenue Growth
- KLG N/A
- MNKD 32.50
- 52 Week Low
- KLG $14.80
- MNKD $3.52
- 52 Week High
- KLG $22.21
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- KLG 62.51
- MNKD 34.29
- Support Level
- KLG $15.58
- MNKD $3.52
- Resistance Level
- KLG $17.92
- MNKD $4.00
- Average True Range (ATR)
- KLG 0.59
- MNKD 0.16
- MACD
- KLG 0.30
- MNKD -0.00
- Stochastic Oscillator
- KLG 84.25
- MNKD 16.67
About KLG WK Kellogg Co
WK Kellogg is the second-largest cereal manufacturer in North America. Its cereal brands include Special K, Frosted Flakes, Raisin Bran, Froot Loops, Frosted Mini-Wheats, Kashi, Corn Flakes, Rice Krispies, Apple Jacks, and Bear Naked. The company was spun off from the former Kellogg business, now known as Kellanova, where the former firm's global snacks portfolio and international cereal brands are now housed. WK Kellogg, which began trading independently in October 2023, generates the bulk of its sales (about 88% of its fiscal 2024 base) in the US.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.